The use of botulinum toxin for the treatment of neurogenic detrusor overactivity was first described in 2000 and thereafter botulinum toxin has also been used in non-neurogenic overactive bladder.
In current guidelines intravesical injection of onabotulinumtoxin A in refractory patients is recommended. Our aim is to provide some clinically relevant recommendations from the Working Group Urologische Funktionsdiagnostik und Urologie der Frau for diagnostics and treatment with onabotulinumtoxin A of patients with non-neurogenic overactive bladder.
Written by:
Bauer RM, Seif C, Bschleipfer T, Reitz A, Schultz-Lampel D. Are you the author?
Urologische Klinik und Poliklinik, Klinikum der Universität München - Campus Großhadern, Ludwig-Maximilians-Universität, Marchioninistraße 15, 81377, München, Deutschland.
Reference: Urologe A. 2014 Nov 14. Epub ahead of print.
doi: 10.1007/s00120-014-3658-2
PubMed Abstract
PMID: 25391442